Your browser doesn't support javascript.
loading
Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis.
Zhou, Shulin; Jiang, Yi; Luo, Chengyan; Yuan, Lin.
Afiliación
  • Zhou S; Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
  • Jiang Y; Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
  • Luo C; Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
  • Yuan L; Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Expert Rev Anticancer Ther ; 24(1-2): 59-69, 2024.
Article en En | MEDLINE | ID: mdl-38174379
ABSTRACT

BACKGROUND:

Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) treatment for ovarian cancer (OC) are ever-changing. This study aimed to compare the efficacy and overall safety of available PARPi as maintenance therapy for BRCA mutation status in patients with newly diagnosed and platinum-sensitive recurrent (PSR) OC patients. RESEARCH DESIGN AND

METHODS:

Relevant RCTs were systematically retrieved from PubMed and Embase until 31 May 2022. Progression-free survival (PFS) and overall survival (OS) based on BRCA mutation status and adverse events (AEs) regardless of mutation were efficacy and safety endpoints.

RESULTS:

In newly diagnosed BRCAm-OC patients, olaparib (HR 0.33; 95% confidence interval [CI] 0.25, 0.43) and other PARPis [niraparib (HR 0.40; 95% CI 0.29, 0.55), rucaparib (HR 0.40; 95% CI 0.21, 0.76) and veliparib (HR 0.44; 95% CI 0.28, 0.69)] had a statistically significant effect on PFS versus placebo. In BRCAm-PSROC patients, Olaparib exhibited significant benefit (HR 0.69; 95% CI 0.54, 0.88) for OS compared to other PARPis. In BRCAwt-PSR OC patients, Olaparib showed a favorable OS benefit than other PARPis (HR 0.84; 95% CI 0.57,1.22). Overall, safety profile of all PARPis was acceptable.

CONCLUSION:

All PARPis showed significant benefit, with olaparib showing greater benefit in newly diagnosed and PSR OC women. REGISTRATION CRD42021288932.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Inhibidores de Poli(ADP-Ribosa) Polimerasas Tipo de estudio: Clinical_trials / Diagnostic_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Inhibidores de Poli(ADP-Ribosa) Polimerasas Tipo de estudio: Clinical_trials / Diagnostic_studies / Systematic_reviews Límite: Female / Humans Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido